Sodium Bicarbonate in Chronic Kidney Disease: Knowing When to Start

The Hidden Trouble of Acid in CKD

Chronic kidney disease quietly chips away at the body's balance. One less obvious problem—metabolic acidosis—shows up as kidneys struggle to keep acid-base status in check. For a long time, these subtle changes rarely get much attention during clinic visits. Still, lowering serum bicarbonate—below 22 mmol/L, in most labs—offers a strong signal that this acid is building up.

This low-grade acidosis doesn’t just make blood tests look worse. Weak bones, shrinking muscles, and worsening kidney function can all link back to acid that hasn’t been cleared well enough. Patients often come in feeling tired or losing muscle, but blame “just getting older.” Their bones may break easily. At times, acid levels sneak down before obvious symptoms appear.

Why Waiting Can Hurt More Than Help

Over my years working with patients with early kidney disease—most holding steady in stage 3 or stage 4—those with bicarb under 22 mmol/L rarely report dramatic drops in quality of life overnight. But study after study shows the long-term picture matters. One 2020 analysis found people with low bicarb had much higher risks for needing dialysis, cardiovascular problems, and bone disease. This isn’t just theory. Outcomes truly worsen for the quiet-overlooked cases who don’t get treated early.

People often ask, “Shouldn’t we start with diet?” Real foods high in fruits and vegetables give an alkaline load, helping cut acid, but some folks can’t eat enough, especially with potassium restrictions. For them, pills become the practical way forward. Sodium bicarbonate—simple baking soda—pushes blood bicarb levels up, lessening the ongoing stress on bones and kidneys.

Choosing the Right Time for Treatment

Most guidelines suggest acting when bicarb falls under 22 mmol/L. My hands-on experience matches the numbers. A well-timed soda tablet program, monitored every couple of months, steadies metabolic acidosis and improves strength for many. Kidney Disease: Improving Global Outcomes (KDIGO) and other groups urge starting oral alkali therapy once that threshold is crossed—unless someone has major risks like heart failure or advanced fluid overload.

Sodium load from these pills can raise blood pressure or swelling, so careful selection matters. In most outpatient cases, adjusting pills works well—patients rarely need inpatient care to address acidosis in stable CKD. The newer potassium-based alkalis suit those with sodium-sensitive hypertension, but cost and availability still get in the way for many uninsured people.

Balancing Practical Steps and Future Research

We need broader efforts in food education and individual meal planning, so people can reduce acid without so many pills. Still, for many struggling to keep healthy potassium, sodium bicarbonate remains the staple. Future studies may help pinpoint which patients benefit the most or least—especially in late-stage CKD or those at high cardiovascular risk.

Starting sodium bicarbonate when bicarb drops below 22 mmol/L, after reviewing diet and checking cardiovascular status, often saves more than it risks. Ignoring low bicarb doesn’t protect kidneys—it usually lets them slip downhill faster.

References: KDIGO 2020 CKD guidelines; “Metabolic Acidosis in CKD”—New England Journal of Medicine, 2022; “Oral Bicarbonate Therapy and Renal Outcomes”—JASN, 2020.